Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

3D Systems Shares Tick Lower, Below $38 Level; Hearing Craig-Hallum Downgrades To Hold In Mid-Day Note

https://twitter.com/sbwcws/status/1425160654831431684

byBenzinga Newsdesk

August 10, 2021

1 minute read

3D Systems downgraded to Hold at Craig-Hallum after 'outsized' move higher$DDD

— ALGO BOT NEWS (@sbwcws) August 10, 2021

Citigroup Maintains Buy on LPL Finl Hldgs, Raises Price Target to $228

By Benzinga Newsdesk

Today, 6:40 AM

Citigroup analyst William Katz maintains LPL Finl Hldgs (NASDAQ:LPLA) with a Buy and raises the price target from $220 to $228.

LPLA

Nio Begins Shipping Charging Infrastructure To Norway Ahead Of September Deadline For Commencing Operations of Power Unit

By Shanthi Rexaline

Today, 6:40 AM

NIO Inc.'s (NYSE: NIO) Norwegian foray appears on track, according to an update provided by the electric vehicle manufacturer.

NIO

Alliance Data Systems: Q4 Earnings Insights

By Benzinga Insights

Today, 6:40 AM

Alliance Data Systems (NYSE:ADS) reported its Q4 earnings results on Thursday, January 27, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

ADS

Legal
News

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted For VPO-227, A Novel Candidate For The Treatment Of Cholera

By Benzinga Newsdesk

Today, 6:40 AM

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VPO-227 for the treatment of cholera.

VNDA

3D Systems Shares Tick Lower, Below $38 Level; Hearing Craig-Hallum Downgrades To Hold In Mid-Day Note

Related Posts

Citigroup Maintains Buy on LPL Finl Hldgs, Raises Price Target to $228

Nio Begins Shipping Charging Infrastructure To Norway Ahead Of September Deadline For Commencing Operations of Power Unit

Alliance Data Systems: Q4 Earnings Insights

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted For VPO-227, A Novel Candidate For The Treatment Of Cholera